High-throughput RNA sequencing transcriptome analysis of ABC-DLBCL reveals several tumor evasion strategies

References

• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Testoni M, Zucca E, Young KH, et al. Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol. 2015;26(6):1069–1080.
   PubMed Web of Science ®Google Scholar
• Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417–1429.
   PubMed Web of Science ®Google Scholar
• Walewski J. Aggressive B-cell lymphoma: chasing the target. J Investig Med. 2020;68(2):331–334.
   PubMed Web of Science ®Google Scholar
• Lodhi N, Tun M, Nagpal P, et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget. 2020;11(44):4045–4073.
   PubMedGoogle Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165.
   PubMed Web of Science ®Google Scholar
• Privette LM, Benight NM, Wagh PK, et al. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Oncogene. 2015;34(18):2325–2336.
   PubMed Web of Science ®Google Scholar
• Pilarczyk M, Kouril M, Shamsaei B, et al. Connecting omics signatures of diseases, drugs, and mechanisms of actions with iLINCS. bioRxiv. 826271; 2019.
   Google Scholar
• Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991–9996.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Glover P, Taylor J, et al. Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance. Br J Haematol. 2021;192(3):599–604.
   PubMed Web of Science ®Google Scholar
• Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–2856.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–119.
   PubMed Web of Science ®Google Scholar
• Gayle S, Landrette S, Beeharry N, et al. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. Blood. 2017;129(13):1768–1778.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
   PubMed Web of Science ®Google Scholar
• Mlacki M, Kikulska A, Krzywinska E, et al. Recent discoveries concerning the involvement of transcription factors from the grainyhead-like family in cancer. Exp Biol Med. 2015;240(11):1396–1401.
   Web of Science ®Google Scholar
• Tian R, Zuo X, Jaoude J, et al. ALOX15 as a suppressor of inflammation and cancer: lost in the link. Prostaglandins Other Lipid Mediat. 2017;132:77–83.
   PubMed Web of Science ®Google Scholar
• Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med. 2009;206(5):1149–1166.
   PubMed Web of Science ®Google Scholar
• Kloth JN, Gorter A, Fleuren GJ, et al. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol. 2008;215(3):222–230.
   PubMed Web of Science ®Google Scholar
• Kaiserman D, Bird PI. Control of granzymes by serpins. Cell Death Differ. 2010;17(4):586–595.
   PubMed Web of Science ®Google Scholar
• Joosten M, Ginzel S, Blex C, et al. A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma. Mol Oncol. 2016;10(8):1232–1244.
   PubMed Web of Science ®Google Scholar
• Ying J, Li H, Cui Y, et al. Epigenetic disruption of two proapoptotic genes MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter. Leukemia. 2006;20(6):1173–1175.
   PubMed Web of Science ®Google Scholar
• Blenk S, Engelman J, Weniger M, et al. Germinal center B cell-like (GCB) and activated B cell-like (ABC) type of diffuse large B cell lymphoma (DLBCL): analysis of molecular predictors, signatures, cell cycle state and patient survival. Cancer Inform. 2007;12(3):399–420.
   Google Scholar
• Kapoor I, Li Y, Sharma A, et al. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. 2019;10(12):924.
   PubMedGoogle Scholar
• Chen J, Ge X, Zhang W, et al. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma. Theranostics. 2020;10(7):3151–3163.
   PubMed Web of Science ®Google Scholar
• Mathews Griner LA, Guha R, Shinn P, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A. 2014;111(6):2349–2354.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2020;95(4):362–371.
   PubMed Web of Science ®Google Scholar
• Ge XH, Zhu GJ, Geng DQ, et al. Metformin protects the brain against ischemia/reperfusion injury through PI3K/Akt1/JNK3 signaling pathways in rats. Physiol Behav. 2017;170:115–123.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng X, Wang Y, et al. Effect of PI3K/Akt/mTOR signaling pathway on JNK3 in Parkinsonian rats. Exp Ther Med. 2018;17(3):1771–1775.
   PubMed Web of Science ®Google Scholar
• Li Z, Mbah NE, Overmeyer JH, et al. The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma. BMC Cancer. 2019;19(1):77.
   PubMedGoogle Scholar
• Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanism of drug resistance and sensitivity. Int J Mol Sci. 2020;21(3):1102.
   PubMed Web of Science ®Google Scholar